Animal

Signet Jewelers Announces Timing Of Fiscal 2022 Second Quarter Earnings Release And Conference Call

Retrieved on: 
Thursday, August 5, 2021
New York Stock Exchange, Sig, Animal, Broadcasting, Silviculture

HAMILTON, Bermuda, Aug. 5, 2021 /PRNewswire/ --Signet Jewelers Limited (NYSE: SIG) intends to announce its second quarter results at approximately 7:00 a.m.

Key Points: 
  • HAMILTON, Bermuda, Aug. 5, 2021 /PRNewswire/ --Signet Jewelers Limited (NYSE: SIG) intends to announce its second quarter results at approximately 7:00 a.m.
  • ET on Thursday, September 2, 2021.
  • On that date there will be a conference call at 8:30 a.m.
  • ET and a simultaneous audio webcast available at www.signetjewelers.com .

CARS Reports Second Quarter 2021 Results

Retrieved on: 
Thursday, August 5, 2021
Company, EDGAR, Table, Fuel (video game), Adjustment, Cash flow, U.S. Securities and Exchange Commission, Solution, Technology, Dealer's Choice (game show), Investment, Industry, Cars.com, Earnings before interest, taxes, depreciation and amortization, Adobe Experience Cloud, Provinces of Greece, GM, Adoption, Annual report, Security (finance), Webcast, Depreciation, Time, Original equipment manufacturer, Program, Productivity-improving technologies, Growth, COVID-19, Sumathi Best Television Current Reporting Award, Sonia, CARS, Multi, Awareness, User (computing), New York Stock Exchange, Income tax, Public expenditure, Knowledge, Consultant, GAAP, Acquisition, Forward-looking statement, Lithium, Video game, Bookkeeping, Health insurance, Animal, Pharmaceutical industry, Car dealership, Online shopping, Bank, Public relations

(NYSE: CARS)("CARS" or the "Company"), a leading digital marketplace and solutions provider for the automotive industry, today released its financial results for the quarter ended June 30, 2021.

Key Points: 
  • (NYSE: CARS)("CARS" or the "Company"), a leading digital marketplace and solutions provider for the automotive industry, today released its financial results for the quarter ended June 30, 2021.
  • Revenue for the second quarter totaled $155.5 million, an increase of $53.5 million, or 52%, compared to the second quarter of 2020, which reflects the impact of the financial relief the Company provided to its dealer customers.
  • Average Monthly Unique Visitors in the second quarter increased 16% and Traffic increased 10%, compared to the second quarter of 2020.
  • Dealer Customers totaled 18,845 at the end of the second quarter, a 5% increase compared to the prior year period.

BCE reports second quarter 2021 results

Retrieved on: 
Thursday, August 5, 2021
Acceleration, Tablet, Bank, Research, U.S. Securities and Exchange Commission, Investment, Public expenditure, Forward-looking statement, Pacific Bell Wireless, Common Era, Season, Acquisition, Earnings before interest, taxes, depreciation and amortization, Bell, Immunity, Adoption, Lists of disasters, Annual report, Risk, Government, Bank of Canada, Bell Media, Mental health, Language, Program, Growth, Bell Let's Talk, Wireless home phone, COVID-19, Advertising, Workplace, ESG, EPS, News, Leadership, Pandemic, Tax, Communication, Radio, Epidemic, Climate change, Failure, Internet, Consultant, LTE, Sport, Data monetization, Ott, Vaccination, Environment, Private Securities Litigation Reform Act, LTE Advanced, Information technology, Risk management, Bookkeeping, Animal, Mobile phone, Retail

The forward-looking statements contained in this news release describe our expectations as of August 5, 2021 and, accordingly, are subject to change after such date.

Key Points: 
  • The forward-looking statements contained in this news release describe our expectations as of August 5, 2021 and, accordingly, are subject to change after such date.
  • Notably, it is assumed that broad immunity is achieved in the third quarter of 2021 in Canada; later in 2021 in the U.S., most other advanced economies and China; and in 2022 in other emerging-market economies.
  • We caution that the foregoing list of risk factors is not exhaustive and other factors could also adversely affect our results.
  • We encourage investors to also read BCE's 2020 Annual MD&A dated March 4, 2021 (included in BCE's 2020 Annual Report) and BCE's 2021 First and Second Quarter MD&As dated April 28, 2021 and August 4, 2021, respectively, for additional information with respect to certain of these and other assumptions and risks, filed by BCE with the Canadian provincial securities regulatory authorities (available at Sedar.com ) and with the U.S. Securities and Exchange Commission (available at SEC.gov ).

ELYSEE Earns $2,049,529 ($0.07 per Share) During the Three Months Ended June 30, 2021

Retrieved on: 
Thursday, August 5, 2021
Hydrogen, Company, Chief executive officer, Black–Scholes model, Investment, Logic, AngloGold Ashanti, Earnings before interest, taxes, depreciation and amortization, LightWave 3D, Miner, United States, Plant, Vanadium, Mission statement, GIP, Electricity, Water, NAV, Silver, ESG, USV, Gold, Life Partners, Inc., Sale, Hyundai Motor Company, MOU, ELC, Biophysical environment, Social, Aluminium, Income, GAAP, Animal, Ridesharing company, Lithium, Cryptocurrency, Security (finance)

Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - Elysee Development Corp. (TSXV: ELC) is pleased to announce its unaudited financial results for the three and six months ended June 30, 2021 ("Q2 2021").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - Elysee Development Corp. (TSXV: ELC) is pleased to announce its unaudited financial results for the three and six months ended June 30, 2021 ("Q2 2021").
  • Highlights from the Q2 2021 results include:
    Net earnings of $2,049,529 ($0.07 per share) in Q2 2021 as compared to earnings of $53,271 in Q1 2021.
  • Net Asset Value per share increased from $0.64 as of March 31, 2021 to $0.72 per share as of June 30, 2021.
  • Guido Cloetens, the Chairman and CEO of Elysee, stated:
    "We are very pleased with our solid performance in Q2 2021.

BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones

Retrieved on: 
Thursday, August 5, 2021
Hereditary angioedema, Medicines and Healthcare products Regulatory Agency, European Commission, Union, Insurance, PIK, BioCryst Pharmaceuticals, Research, United Kingdom, Safety, Yellow fever, Royal commission, Annual report, EMA, EC, IgA nephropathy, Park, Food and Drug Administration, Paroxysmal nocturnal hemoglobinuria, ID, Security (finance), United, PNH, Growth, Galidesivir, Hae, Marburg virus disease, GLOBE, U.S. Securities and Exchange Commission, Investment, Webcast, Government, Attack, Health care, Oral medicine, Patient, COVID-19, NHI, Immunoglobulin A, PMDA, Nasdaq, Ministry, European Academy of Management, Physician, Disease, Lithium, Pharmaceutical industry, Animal

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the second quarter ended June 30, 2021, and provided a corporate update.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the second quarter ended June 30, 2021, and provided a corporate update.
  • On July 10, 2021, the company announced data presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2021.
  • Selling, general and administrative expenses for the second quarter of 2021 increased to $26.3 million, compared to $13.9million in the second quarter of 2020.
  • Interest expense was $13.5 million in the second quarter of 2021, compared to $2.9 million in the second quarter of 2020.

TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 5, 2021
Acute lymphoblastic leukemia, The Retreat, Cancer, Non-small-cell lung carcinoma, Safety, Clinical trial, Tenant, Annual report, Private Securities Litigation Reform Act, Review, Thalassemia, ESMO, Oncology, Lung cancer, European Society for Medical Oncology, Research, Therapy, Risk, European Society of Gene and Cell Therapy, Transfusion, IND, Limited liability company, Partnership, TCR, Aall, Congress, National Hockey League, Oslo-Fergene, GLOBE, Company, Conference, U.S. Securities and Exchange Commission, Investment, Cholangiocarcinoma, Lymphatic system, Adoption, HLA, Program, Patient, COVID-19, Ovarian cancer, Certification, Adult, Nasdaq, D, Cell, Quality control, Pharmaceutical industry, Animal, Cryptocurrency

Net cash used in operations was $15.0 million for the second quarter of 2021 compared to $16.0 million for the second quarter of 2020.

Key Points: 
  • Net cash used in operations was $15.0 million for the second quarter of 2021 compared to $16.0 million for the second quarter of 2020.
  • R&D Expenses: Research and development expenses were $18.6 million for the second quarter of 2021 compared to $12.9 million for the second quarter of 2020.
  • G&A Expenses: General and administrative expenses were $5.7 million for the second quarter of 2021 compared to $3.8 million for the second quarter of 2020.
  • Net Loss: Net loss was $24.3 million for the second quarter of 2021 compared to $16.2 million for the second quarter of 2020.

Lee Enterprises reports strong third quarter results with revenue and Adjusted EBITDA growth

Retrieved on: 
Thursday, August 5, 2021
Pillar, Company, Adjustment, Public expenditure, Webcast, Digital, Berkshire Hathaway, Industry, Property tax, Lee Enterprises, Software as a service, Private Securities Litigation Reform Act, Earnings before interest, taxes, depreciation and amortization, Super Mario, Central Time, The Buffalo News, TownNews, Partnership, Advertising, Contract, Growth, COVID-19, Legislation, News, LEE, Capital, GAAP, Capital expenditure, Acquisition, Nasdaq, GLOBE, Animal, Video game, Music, Bank, Public relations, Bookkeeping, Life insurance, Credit, Audit

DAVENPORT, Iowa, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Lee Enterprises, Incorporated (NASDAQ: LEE), a leading provider of high quality, trusted, local news, information and a major platform for advertising in 77 markets, today reported third quarter fiscal 2021 financial results(2) for the period ended June 27, 2021. On a GAAP basis, total operating revenue was $196.5 million and net income totaled $3.7 million in the third quarter.

Key Points: 
  • We have made significant progress on our Three Pillar Digital Growth Strategy and our third quarter results clearly demonstrate that we are on a strong path forward to driving more recurring, sustainable revenue.
  • I am extremely proud to report that we posted 7.6% growth in total operating revenue, 48.3% growth in total digital revenue, 90.3% growth in Amplified revenue, 36.4% growth in digital-only audience revenue, and our second straight quarter of Adjusted EBITDA growth.
  • "Almost 55% of our total operating revenue, representing $108 million, is subscription-based recurring revenue and, includes subscription revenue, revenue at TownNews and Amplified revenue.
  • Total digital revenue, including digital advertising, digital subscription and digital services revenue, was $65.6 million and represented 33.4% of total operating revenue.

Antares Pharma Reports Second Quarter 2021 Financial and Operating Results

Retrieved on: 
Thursday, August 5, 2021
Company, PK, Pfizer, Research, U.S. Securities and Exchange Commission, Testosterone, Forward-looking statement, Industry, Prescription, Eastern Time Zone, Annual report, Eastern, Antares, Private Securities Litigation Reform Act, IND, Review, Hydrocortisone, Growth, Patient, AMAG, COVID-19, Letter, Ferring Pharmaceuticals, GLOBE, Total, Enlight Quickshot, Food and Drug Administration, Net income, Terminology, NDA, Income, Marketing, AMAG Pharmaceuticals, Nasdaq, Security (finance), Risk, Pharmaceutical industry, Lithium, Music, Animal

EWING, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today reported financial and operating results for the second quarter ended June 30, 2021 with record revenue of $45.0 million and net income of $4.4 million, or $0.03 per basic and diluted earnings per share.

Key Points: 
  • Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, We believe our strong second quarter performance highlights the growth opportunities that prevail across our diversified business.
  • XYOSTED total prescriptions in the second quarter 2021 increased 50% year-over-year and 15% sequentially from first quarter 2021, according to IQVIA.
  • In June 2021, Antares made a $15.0 million principal prepayment and reduced our loan balance with Hercules Capital to $25.0 million.
  • The Antares management team will provide a Company update and review the second quarter and year-to-date financial results via conference call and webcast today, August 5, 2021, at 8:30am ET (Eastern Time).

Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, August 5, 2021
Human, Cancer, Safety, Tablet, Acute myeloid leukemia, Private Securities Litigation Reform Act, Diarrhea, AST, Orthopoxvirus, Smallpox, Food and Drug Administration, ID, Profile, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pregnancy, Research, Related, Investor, Incidence, Mortality, IND, Male, Animal, TRAIL, Nausea, Fertility, Cidofovir, Sodium, Conference call, Glioma, Food, Nasdaq, GLOBE, Company, Conference, Acquisition, Immunodeficiency, U.S. Securities and Exchange Commission, Forward-looking statement, Abdominal pain, Trial of the century, Bilirubin, Dash, AML, Common, Infertility, Patient, Alt, Vomiting, Risk, Adult, DNA, NDA, Disease, Pharmaceutical industry, Vaccine, Lithium, Birth control

DURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2021 and provided an operational update.

Key Points: 
  • Conference Call at8:30 a.m. ETToday
    DURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2021 and provided an operational update.
  • Revenues for the second quarter of 2021 decreased to $0.4 million, compared to $1.4 million for the same period in 2020.
  • Research and development expenses increased to $13.8 million for the second quarter of 2021, compared to $8.6 million for the same period in 2020.
  • Chimerix will host a conference call and live audio webcast to discuss second quarter 2021 financial results and provide a business update today at 8:30 a.m.

South Africa Skincare Market Report 2021-2026: $663 Million Market Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021
Cosmetics, Retail, Serum, United States dollar, Technology, Method, Skin, Natura & Co, Health, COVID-19, 2009 Davis Cup, Awareness, Beiersdorf, Profile, Compound annual growth rate, Overalls, Animal, Cosmetics, Online shopping

The "South Africa Skincare Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "South Africa Skincare Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The skincare market has been witnessing significant growth due to the increasing health and hygiene consciousness among consumers, owing to the impact of the COVID-19 pandemic.
  • The pandemic led to a shift in consumer priorities in 2020, with a focus on overall health and wellbeing.
  • South Africa's skincare market is highly fragmented due to the prominence of several small players in the market.